IP Library Granted Patent US 10,328,126
Granted Patent B2
US 10,328,126 · App. 15/457,656 · Granted Jun 25, 2019

Peptides and compositions for treatment of joint damage

Inventors: Kristen Johnson (Santee, CA); Jian Shi (San Diego, CA)
Assignee: Novartis AG
A61K38/1891A61K31/192A61K31/198A61K31/593A61K31/728A61K35/32A61K38/014A61K38/1825A61K38/1875A61K38/225A61K45/06C07K14/515C12N5/0655C12N2501/17C12N2506/1346
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,328,126
App. No.
15/457,656
Granted
Jun 25, 2019
Kind
B2
Abstract

The present invention provides new protease-resistant polypeptides, as well as compositions and methods for treating, ameliorating or preventing conditions related to joint damage, including acute joint injury and arthritis.

Claims (20)

1. A method of inducing differentiation of mesenchymal stem cells into chondrocytes, the method comprising contacting mesenchymal stem cells in the joint of a subject suffering from arthritis or cartilage damage with an effective amount of a polypeptide comprising an amino acid sequence that has at least 95% amino acid sequence identity to an amino acid sequence selected from any one of SEQ ID NOs: 58-70, wherein the amino acid at position 423, as determined with reference to SEQ ID NO: 1, is deleted, to induce differentiation of the mesenchymal stem cells into chondrocytes, wherein said contacting is achieved by intra-articular delivery of the polypeptide to said subject.

2. The method of claim 1 , wherein the subject is a human subject.

3. The method of claim 2 , wherein the arthritis is osteoarthritis, traumatic arthritis, or autoimmune arthritis.

4. The method of claim 2 , wherein the polypeptide comprises an amino acid sequence selected from any one of SEQ ID NOs: 58-70.

5. The method of claim 2 , wherein the polypeptide consists of an amino acid sequence selected from any one of SEQ ID NOs: 58-70.

6. The method of claim 2 , wherein the polypeptide is PEGylated.

7. The method of claim 2 , wherein the polypeptide is fused to a heterologous peptide selected from any of human serum albumin (HSA), immunoglobulin heavy chain constant region (Fc), polyhistidine, glutathione S transferase (GST), thioredoxin, protein A, protein G, or maltose binding protein (MBP), or a fragment thereof, wherein the heterologous peptide is fused at either the amino-terminal end or the carboxy-terminal end of the polypeptide.

8. The method of claim 2 , further comprising administering one or more additional chondrogenic factors to the subject.

9. The method of claim 2 , further comprising performing a surgical procedure on an affected joint of the subject.

10. A method of treating or ameliorating arthritis or cartilage damage in a joint of a subject in need thereof comprising administering to the subject at a site in need of treatment or by intra-articular delivery a therapeutically effective amount of a polypeptide comprising an amino acid sequence that has at least 95% amino acid sequence identity to an amino acid sequence selected from any one of SEQ ID NOs: 58-70, wherein the amino acid at position 423, as determined with reference to SEQ ID NO: 1, is deleted.

11. The method of claim 10 , wherein the subject is a human.

12. The method of claim 10 , wherein the arthritis is osteoarthritis, trauma traumatic arthritis, or autoimmune arthritis.

13. The method of claim 10 , wherein the polypeptide comprises an amino acid sequence selected from any one of SEQ ID NOs: 58-70.

14. The method of claim 10 , wherein the polypeptide consists of an amino acid sequence selected from any one of SEQ ID NOs: 58-70.

15. The method of claim 10 , wherein the polypeptide is PEGylated.

16. The method of claim 10 , wherein the polypeptide is fused to a heterologous peptide selected from any of human serum albumin (HSA), immunoglobulin heavy chain constant region (Fc), polyhistidine, glutathione S transferase (GST), thioredoxin, protein A, protein G, or maltose binding protein (MBP), or a fragment thereof, wherein the heterologous peptide is fused at either the amino-terminal end or the carboxy-terminal end of the polypeptide.

17. The method of claim 10 , wherein the polypeptide is administered in a matrix or biocompatible scaffold.

18. The method of claim 10 , further comprising administering one or more additional chondrogenic factors to the subject.

19. The method of claim 10 , further comprising performing a surgical procedure on an affected joint of the subject.

20. The method of claim 10 , further comprising performing one or more of the following procedure to the subject: bone marrow stimulation, cartilage replacement, autologous chondrocyte implantation (ACI), matrix-induced autologous chondrocyte implantation (MACI).

Assignments (6)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 7, 2019
From: JOHNSON, KRISTEN; SHI, JIAN
To: NOVARTIS INSTITUTE FOR FUNCTIONAL GENOMICS, INC.
Reel/Frame 049100/0260 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 7, 2019
From: NOVARTIS INSTITUTE FOR FUNCTIONAL GENOMICS, INC.
To: IRM LLC
Reel/Frame 049100/0267 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 7, 2019
From: JOHNSON, KRISTEN; SHI, JIAN
To: NOVARTIS INSTITUTE FOR FUNCTIONAL GENOMICS, INC.
Reel/Frame 049100/0284 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 7, 2019
From: NOVARTIS INSTITUTE FOR FUNCTIONAL GENOMICS, INC.
To: IRM LLC
Reel/Frame 049100/0297 →
MERGER Recorded May 7, 2019
From: IRM LLC
To: NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD.
Reel/Frame 049100/0305 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 7, 2019
From: NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD.
To: NOVARTIS AG
Reel/Frame 049100/0313 →
Continuity (4)
Division 14772209
Provisional Application 61938123 · Feb 10, 2014
Provisional Application 61775400 · Mar 8, 2013
Related Publication 20170252407A1 · Sep 7, 2017